COVID-19 Vaccine Supply Chain and Regulatory Transparency Technical Symposium
10:00 – 10:15
SESSION 1: Opening
- Ms Anabel González, Deputy Director-General, World Trade Organization
- Dr Mariângela Batista Galvão Simão, Assistant Director-General, World Health Organization
- Mr Ricardo Treviño Chapa, Deputy Secretary-General, World Customs Organization
10:15 – 11:30
SESSION 2: Mapping vaccine manufacturing and trade
- What are the latest projections on COVID-19 vaccine manufacturing output?
- What can supply chain mapping exercises tell us about vaccine manufacturing production and related value chains?
- Vaccine producers are experiencing bottlenecks in their supply chains. Which types of problems are being experienced and what can policy makers do to address them?
MODERATOR: Robert Koopman, Chief Economist, World Trade Organization
- Mr Rasmus Bach Hansen, CEO & Founder, Airfinity
- Dr Matthew Downham, Sustainable Manufacturing Lead, Coalition for Epidemic Preparedness Innovations
- Ms Giulia del Brenna, Head of Unit for Strategy and Regulation: Single Market and Industrial Policy, Directorate General for Internal Market, Industry, Entrepreneurship and SMEs, (DG Grow) and European Commission Task Force for the Industrial Scale-up of COVID-19 vaccine production
- Mr Andrew Wilson, Global Policy Director, International Chamber of Commerce
- Mr Hongyi Wang, Vice-President, International Business, CanSino Biologics Inc
- Ms Laetitia Bigger, Vaccines Policy Director, International Federation of Pharmaceutical Manufacturers and Associations
Five steps to urgently advance COVID-19 vaccine equity
- Ms Elsie M. Soto, Vice-President, Supply Chain, Emerging Markets, Pfizer
- Mr Rajiv Gandhi, CEO & Managing Director, Hester Biosciences
- Mr Carel du Marchie Sarvaas, Executive Director, Health for Animals
11:30 – 13:00
SESSION 3: Mapping cross-border movement of vaccine inputs
- What are the vaccines inputs that matter and how are they traded across borders?
- Are trade measures creating bottlenecks in input supply chains, and if so, where and why?
- What approaches can Members and other stakeholders take to facilitate the efficient cross-border movement of vaccine inputs?
- What could be done to improve the monitoring and facilitate these cross-border movements?
MODERATOR: Suja Rishikesh Mavroidis, Director, Market Access Division, WTO
- Mr Dayong Yu, Chief, Market Access Intelligence Section, Economic Research and Statistics Division, World Trade Organization and Mr Roy Santana, Counsellor, Market Access Division
- Ms Gael Grooby, Deputy Director, Tariff and Trade Affairs Directorate, World Customs Organization
- Ms Silvia Sorescu, Trade Policy Analyst, OECD
OECD webpage on “The race to vaccinate: Understanding the policy challenges around COVID-19 vaccines”
OECD (2021), “Using trade to fight COVID-19: Manufacturing and distributing vaccines”
OECD (2020), “Trade interdependencies in COVID-19 goods”
OECD (2021), “Access to COVID-19 vaccines: Global approaches in a global crisis”
OECD (2021), “COVID-19 vaccines for developing countries: An equal shot at recovery”
- Mr Chad P. Bown, Reginald Jones Senior Fellow, Peterson Institute for International Economics
The US did not ban exports of vaccine supplies. But more help is needed
Here's how to get billions of COVID-19 vaccine doses to the world
Vaccine Nationalism Will Prolong the Pandemic
The Tragedy of Vaccine Nationalism
The Real Vaccine Procurement Problem
- Mr Ronald Antonio Q. Butiong, Chief, Regional Cooperation and Integration Thematic Group, Sustainable Development and Climate Change Department, Asian Development Bank
ADB’s supply chain mapping tool
- Ms Phyllis Arthur, Vice-president, Infectious diseases and diagnostics policy, Biotechnology Innovation Organization
- Mr Thomas Ellman, Vice-President, Life Sciences and Healthcare, Customer Solutions and Innovation, DHL
Delivering Pandemic Resilience revisited
DHL White Paper
- Mr Christian Piaget, Head Cargo Border Management, APCS-CARGO, International Air Transport Association
Guidance for Vaccine and Pharmaceutical Logistics and Distribution
IATA Action Cargo
IATA COVID-19: Resources for Airlines & Air Transport Professionals
COVID-19 Trade Facilitation Resource Repository
- Mr Jens Hügel, Senior Adviser, International Road Transport Union
15:00 – 16:30
SESSION 4: Promoting transparency and convergence in the regulatory landscape
- What approaches are being used to expedite the regulatory processes needed to get new manufacturing capacity up and running?
- How can we cooperate internationally to quickly and safely manufacture, approve and disseminate needed vaccines, therapeutics and diagnostics?
- How can transparency in the regulatory approval process be strengthened?
- How do we increase regulatory cooperation and capacity building for better future pandemic preparedness?
MODERATOR: Aik Hoe Lim, Director, Trade and Environment Division, WTO
- Dr June Raine, Chief Executive, Medicines and Healthcare products Regulatory Agency, UK
- Dr Rogério Gaspar, Director, Regulation and Prequalification Department, WHO
List of WHO guidance on COVID-19 vaccines
Good regulatory practices in the regulation of medical products
Good reliance practices in the regulation of medical products: high level principles and considerations
WHO Good Regulatory and Reliance Practices Launch Webinar - 29 June 2021
- Dr Yasuhiro Fujiwara, Chief Executive, Pharmaceuticals and Medical Devices Agency, Japan
- Mrs Delese Darko, Chief Executive Officer, Food and Drugs Authority, Ghana
- Mr Rajinder Kumar Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers' Network
- Dr Skhumbuzo Ngozwana, CEO of Kiara Health, Chairman of the Board, Biovac
- Mr Alastair West, Business Plan Coordinator, Pharmaceutical Manufacturing Plan for Africa, UNIDO
- Ms Raj Long, Independent Expert Advisor on Regulation and Access
16:30 – 17:45
SESSION 5: Beyond vaccines: mapping other COVID-19 essential health technologies and trade
- How can value chain mapping techniques be used to chart trade in other COVID-19 essential health technologies?
- What manufacturing, input and regulatory bottlenecks are these COVID-19 essential health technologies facing and why?
MODERATOR: Antony Taubman, Director, Intellectual Property, Government Procurement and Competition Division, WTO
- Mr Aaron Bernstein, Divisional Vice President, Procurement Technical Services, Abbott
- Mr Carlos Eduardo Gouvêa, President, Latin American Alliance for the Development of In Vitro Diagnostics
White Book of Lab Diagnostics
Inter American Coalition for Business Ethics and for Regulatory Convergence
Program of Assessment of Diagnostic Kits for COVID-19
- Ms Tanya Vogt, Executive Officer, South African Medical Device Industry Association
SAMED COVID-19 Vaccine roll-out policy paper
- Dr Trevor Gunn, Vice President for International Relations, Medtronic
- Ms Hemal Shah, Director, IP & Trade Policy, Government Affairs & Policy, Gilead
Problems viewing this page? If so, please contact email@example.com giving details of the operating system and web browser you are using.